AUTOIMMUNE BULLOUS DERMATOSES. DIFFERENTIAL DIAGNOSIS

Cover Page


Cite item

Full Text

Abstract

The review presents modern ideas concerning autoimmune bullous dermatoses (pemphigoid group): Duhring disease, bullous pemphigoid, cicatrizing pemphigus, pemphigoid gestationis, linear IgA bullous dermatosis and acquired bullous epidermolysis. Pathogenesis, clinical manifestations and modern methods of disease diagnostics are reported. Particular attention is paid to the diagnosis of acquired bullous epidermolysis, in which the leading role belongs to the reaction of immunofluorescence. The pathogenetic similarity between bullous pemphigoid, linear IgA dermatosis, cicatrizing pemphigoid and pemphigoid gestationis is shown, which allows us to regard them as a variety of a single pathological process.

About the authors

V. I. Al'banova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: albanova@rambler.ru
Korolenko str., 3, bldg 6, Moscow, 107076, Russia Russian Federation

M. A. Nefedova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Korolenko str., 3, bldg 6, Moscow, 107076, Russia Russian Federation

References

  1. Mihalyi L., Kiss M., Dobozy A. et al. Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis. Clinical and Developmental Immunology 2012; 2012: 369546.
  2. Arbache S. T., Nogueira T.G., Delgado L. et al. Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience. Anais brasileiros de dermatologia 2014; 89(6): 885—889.
  3. Schmidt E., Zillikens D. Pemphigoid diseases. Lancet. 2013; 381(9863): 320—332.
  4. Karpati S. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. Dermatologic Clinics 2011; 29(3): 463-468.
  5. Gawkrodger D.J., Blackwell J.N., Gilmour H.M. et al. Dermatitis herpetiformis diagnosis diet and demography. Gut 1984; 25(2):151—157.
  6. Mobacken H., Kastrup W., Nilsson L. A. Incidence and prevalence of dermatitis herpetiformis in Sweden. Acta Dermato-venereologica 1984; 64(5): 400—404.
  7. Salmi T. T., Hervonen K., Kautiainen H. et al. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol 2011;165(2): 354—359.
  8. Federal clinical recommendations. Dermatovenereology 2015: Skin diseases. Sexually transmitted infections. 5th ed. M.: Delovoy Express, 2016, 768 pp. [Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. М.: Деловой экспресс 2016; 768.]
  9. Jakes A. D., Bradley S., Donlevy L. Dermatitis herpetiformis. Br Med J 2014; 348: 2557.
  10. Mendes F. B., Hissa-Elian A., Abreu M. A. et al. Review: dermatitis herpetiformis. Anais Brasileiros de Dermatologia 2013; 88(4): 594— 599.
  11. Byrne G., Feighery C. F. Celiac Disease: Diagnosis. Methods in Molecular Biology 2015; 1326: 15—22.
  12. Antiga E., Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clinical, Cosmetic and Investigational Dermatology 2015; 13(8): 257—265.
  13. Rose C., Bröcker E. B., Zillikens D. Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring. Journal der Deutschen Dermatologischen Gesellschaft 2010; 8(4): 265—270.
  14. Tsvetkova G. M., Mordovtsev V. V. et al. Pathomorphology of skin diseases: guidance for physicians. M: 2003, 496. [Цветкова Г. М., Мордовцев В. В. и др. Патоморфология бо- лезней кожи: руководство для врачей. М: 2003; 496.]
  15. Lever’s Histopathology of the Skin, 10th edition. David E. Elder, Editor-in-Chief, Philadelphia: Wolters Kluwer/Lippincott Williams & Williams, 2008; 1408.
  16. Warren S.J., Cockerell C.J. Characterization of a subgroup of patients with dermatitis herpetiformis with nonclassical histologic features. Am J Dermatopathol 2002; 24(4): 305—308.
  17. Kalaaji A. N., Nicolas M. E. O. Mayo clinic atlas of immunofluorescence in dermatology: patterns and target antigens. CRC Press 2006.
  18. Dieterich W., Laag E., Bruckner-Tuderman L. et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113(1): 133—136.
  19. Kumar V., Jarzabek-Chorzelska M., Sulej J. et al. Tissue transglutaminase and endomysial antibodies-diagnostic markers of glutensensitive enteropathy in dermatitis herpetiformis. Clin Immunol 2001; 98(3): 378—382.
  20. Jordon R. E., Beutner E. H., Witebsky E. et al. Basement zone antibodies in bullous pemphigoid. JAMA 1967; 200: 751—756.
  21. Bagcı I. S., Horvath O. N., Ruzicka T. et al. Bullous pemphigoid. Autoimmunity Reviews. 2017 (in print).
  22. Bernard P., Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol 2017 (in print).
  23. Schneider I., Husz S. Seborrhoic pemphigoid. Hautarzt. 1986; 37(3): 149—151.
  24. Balestri R., Magnano M., La Placa M. et al. Malignancies in bullous pemphigoid: a controversial association. The Journal of dermatology. 2016; 43(2): 125—133.
  25. Liu Z. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. The Keio journal of medicine. 2003; 52(2): 128—133.
  26. Yamase A., Kono T., Ishii N. et al. An autoimmune bullous dermatosis with clinical, histopathological and immunological features of bullous pemphigoid and epidermolysis bullosa acquisita in an adult. Br J Dermatol 2016; 175(4): 790—793.
  27. Terra J. B., Meijer J.M., Jonkman M. F. et al. The n- versus u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol 2013; 169(1): 100—105.
  28. Edwards S., Wakelin S. H., Wojnarowska F. et al. Bullous pemphigoid and epidermolysis bullosa acquisita: Presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol 1998; 15: 184—190.
  29. Yang B., Wang C., Chen S. et al. Accuracy of indirect immunofluorescence on sodium chloride-split skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Ind J Dermatol Venereol Leprol. 2011; 77(6): 677—682.
  30. Feliciani C., Di Muzio M., Mohammad Pour S. et al. “Suction split” as a routine method to differentiate epidermolysis bullosa acquisita from bullous pemphigoid. J Eur Acad Dermatol Venereol 1998; 10(3): 243—247.
  31. Ruhrberg C., Watt F.M. The plakin family: versatile organizers of cytoskeletal architecture. Current Opinion in Genetics and Development 1997; 7(3): 392—397.
  32. Fortuna G., Marinkovich M. P. Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012; 30(1): 38—50.
  33. Guide S. V., Marinkovich M. P. Linear IgA bullous dermatosis. Clin dermatol 2001; 19(6): 719—727.
  34. Zone J.J. Clinical spectrum, pathogenesis and treatment of linear IgA bullous dermatosis. J dermatol 2001; 28(11): 651—653.
  35. Eguia del Valle A., Aguirre Urízar J.M., Martínez Sahuquillo A. Oral manifestations caused by the linear IgA disease. Medicina oral: organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal. 2003; 9(1): 39—44.
  36. Venning V. A. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Immunology and allergy clinics of North America. 2012; 32(2): 245—253.
  37. Collier P.M., Kelly S. E., Wojnarowska F. Linear IgA disease and pregnancy. J Amer Acad Dermatol 1994; 30(3): 407—411.
  38. Onodera H., Mihm M. C. Jr., Yoshida A. et al. Drug‐Induced Linear IgA Bullous Dermatosis. J Dermatol 2005; 32(9): 759—764.
  39. Allen J., Phan T. T., Hughes M. A. et al. The cellular origins of the linear IgA disease target antigens: an indirect immunofluorescence study using cultured human keratinocytes and fibroblasts. Br J Dermatol 2003; 148(5): 945— 953.
  40. Wozniak K., Hashimoto T., Ishii N. et al. Fluorescence overlay antigen mapping using laser scanning confocal microscopy differentiates linear IgA bullous dermatosis from epidermolysis bullosa acquisita mediated by IgA. Br J Dermatol 2013; 168(3): 634—638.
  41. Roh J. Y., Yee C., Lazarova Z. et al. The 120‐ kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. Br J Dermatol 2000; 143(1): 104—111.
  42. Kirzhner M., Jakobiec F. A. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. Seminars in ophthalmology. Taylor & Francis, 2011; 26 (4—5): 270—277.
  43. Lin L., Zeng X., Chen Q. Pemphigus and pregnancy: Analysis and summary of case reports over 49 years. Saudi medical journal. 2015; 36(9): 1033—1038.
  44. Jenkins R. E., Hern S., Black M.M. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Experiment Dermatol 1999; 24(4): 255—259.
  45. Semkova K., Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstetrics Gynecol Reprod Biol 2009; 145(2): 138—144.
  46. Al-Saif F., Elisa A., Al-Homidy A. et al. Retrospective analysis of pemphigoid gestationis in 32 Saudi patients — clinicopathological features and a literature review. J Reprod Immunol 2016; 116: 42—45.
  47. Baum S., Sakka N., Artsi O. et al. Diagnosis and classification of autoimmune blistering diseases. Autoimmunity Reviews. 2014; 13: 482—489.
  48. Ludwig R.J. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol 2013; 2013: 812029.
  49. Gupta R., Woodley D. T., Chen M. Epidermolysis bullosa acquisita. Clin Dermatol 2012; 30: 60—69.
  50. Ishii N., Hamada T., Dainichi T. et al. Epidermolysis bullosa acquisita: What’s new? J Dermatol 2010; 37: 220—230.
  51. Chikin V. V., Znamenskaya L. F., Nefedova M. A. et al. Epidermolysis bullosa acquisita. Vestn Dermatol Venerol 2015; 3: 109—118. [Чикин В. В., Знаменская Л.Ф., Нефедова М. А. и соавт. Приобретенный буллезный эпидермолиз: описание клинического случая. Вестн дерматол венерол 2015; (3): 109—118.]
  52. Albanova V. I., Nefedova M. A. Epidermolysis bullosa acquisita: diagnostic complexity. Vestn Dermatol Venerol 2017 (in print). [Альбанова В. И., Нефедова М. А. Приобретенный буллезный эпидермолиз: сложность диагностики. Вестн дерматол венерол 2017 (в печати).]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Al'banova V.I., Nefedova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies